Previous close | 0.0150 |
Open | 0.0150 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0150 - 0.0150 |
52-week range | 0.0130 - 0.0150 |
Volume | |
Avg. volume | 0 |
Market cap | 34.904M |
Beta (5Y monthly) | 2.28 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0000 |
Earnings date | 25 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept, placebo-controlled, parallel group trial with a six-week treatment period and four weeks of follow up.
Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease (AD). This represents the culmination of the site and screening setup phase of the trial when patient pre-screening for elevated levels of the pTau blood biomarker commenced at multiple clinical sites.
Actinogen Medical Limited ( ASX:ACW ) shareholders will doubtless be very grateful to see the share price up 50% in the...